Rocuronium
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Using no additional tools — this is a direct evidence-pack-to-report writing task, so I’ll produce the report per the v5 template.
Rocuronium: From Neuromuscular Blockade to Migraine Disorder
One-Sentence Summary
Rocuronium is a peripheral, non-depolarizing neuromuscular blocking agent used for skeletal muscle relaxation during general anesthesia and intubation. The TxGNN model’s top prediction links it to Migraine Disorder, but this is supported by only 1 loosely related clinical trial and no literature, and the evidence pack’s own mechanistic review found no plausible pharmacological basis for the connection.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not on file for the India market (drug not marketed, 0 registrations). Per the evidence pack’s own mechanistic notes, rocuronium is a peripheral neuromuscular blocking agent used for muscle relaxation during general anesthesia. |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for rocuronium is not available in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information that is available, rocuronium is a peripheral neuromuscular blocking agent acting at the nicotinic acetylcholine receptor of the neuromuscular junction — its clinical role is skeletal muscle relaxation during surgical anesthesia, not central nervous system modulation.
The evidence pack’s own rationale for the top prediction is explicit that no mechanistic link exists: rocuronium does not cross the blood–brain barrier and has no known action on the trigeminovascular system or CGRP pathway implicated in migraine pathophysiology. This pattern repeats across nearly all 10 TxGNN candidates in this pack (migraine with brainstem aura, cauda equina syndrome, rare dermatologic conditions, IBS, etc.) — each is annotated as having no mechanistic basis, and most have zero supporting clinical trials or literature. The single partial exception is rank 10, “headache disorder” (L4, decision-stage S1, “Research Question”), where one comparative study (PMID 23812022) suggests a rocuronium-sugammadex anesthesia protocol may reduce post-ECT myalgia/headache — but this reflects a reduction in an anesthesia side effect, not treatment of headache as a disease.
Overall, this candidate set does not currently support a repurposing hypothesis for rocuronium. The high TxGNN scores appear to reflect graph-level associations (e.g., co-occurrence in surgical/procedural contexts) rather than genuine pharmacological relevance.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01431326 | N/A | Completed | 3,520 | Pediatric pharmacokinetics study of “understudied drugs” administered per standard of care; rocuronium is one of many study drugs. Not a migraine treatment trial — relevance graded C (likely database co-occurrence artifact). |
Literature Evidence
Currently no related literature available.
India Market Information
Rocuronium is currently not marketed in India under this evidence pack (0 registrations, no license records available).
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are not currently available — flagged as a Blocking-severity data gap, DG001, pending TFDA label retrieval.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (migraine disorder) has no mechanistic plausibility, minimal clinical trial support (1 trial, relevance grade C), and no literature evidence — consistent with an L5, prediction-only evidence level. Across all 10 candidates returned, none rise above L4, and the one L4/S1 candidate (headache disorder) reflects an anesthesia side-effect signal rather than a disease-treatment hypothesis. Compounding this, core drug-level data (MOA, TFDA warnings/contraindications) are marked as data gaps, one of which is Blocking severity — meaning this candidate cannot yet even complete a basic safety screen.
To proceed, the following is needed:
- Resolve DG001 (Blocking): retrieve and parse TFDA label for warnings/contraindications before any S1 safety evaluation
- Resolve DG002 (High): confirm mechanism of action via DrugBank API to properly assess mechanistic plausibility
- If pursuing the headache-disorder signal (rank 10) instead, reframe the hypothesis around anesthesia-associated myalgia/headache reduction (not migraine treatment) and seek confirmatory studies beyond the single case-comparative report (PMID 23812022)
- Given the drug is not currently marketed in India, market-entry feasibility would also need separate evaluation independent of the repurposing signal
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.